| Property | Value |
|---|---|
| Gene Symbol | CTSB |
| Full Name | Cathepsin B |
| Chromosomal Location | 8p23.1 |
| NCBI Gene ID | 1508 |
| OMIM ID | 116810 |
| Ensembl ID | ENSG00000164733 |
| UniProt ID | P07846 |
| Encoded Protein | Cathepsin B |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease |
CTSB encodes cathepsin B, a lysosomal cysteine protease of the papain family that plays critical roles in protein degradation, antigen processing, and cellular homeostasis. Once viewed primarily as a house-keeping protease, cathepsin B has emerged as a key player in neurodegenerative disease pathogenesis through its involvement in amyloid-beta (Aβ) degradation, tau cleavage, alpha-synuclein processing, and neuroinflammation[1][2].
The dual nature of cathepsin B in neurodegeneration represents both a therapeutic challenge and opportunity. While it can degrade Aβ and potentially reduce amyloid burden, it may also contribute to neuronal death through activation of apoptotic pathways and generation of toxic Aβ fragments. This complex role has made cathepsin B a subject of intense research interest.
The CTSB gene spans approximately 29 kb on chromosome 8p23.1 and consists of 13 exons encoding a preproprotein of 339 amino acids. The gene structure is conserved among mammalian species.
| Feature | Details |
|---|---|
| Chromosome | 8p23.1 |
| Strand | Plus strand |
| Exons | 13 |
| Transcript length | ~1.5 kb coding region |
| Promoter elements | TATA box, GC-rich regions |
Cathepsin B is highly conserved across species:
| Species | Identity | Notes |
|---|---|---|
| Human | Reference | Full length |
| Mouse | 91% | Conserved function |
| Rat | 90% | Model organism |
| Zebrafish | 67% | Expressed in brain |
| Drosophila | 58% | Homolog cathepsin B |
Cathepsin B is synthesized as a preproenzyme requiring activation:
Cathepsin B employs a cysteine protease mechanism:
| Residue | Role |
|---|---|
| Cys119 | Catalytic cysteine (nucleophile) |
| His279 | Catalytic histidine (base) |
| Asn299 | Oxyanion hole formation |
| Gln23 | Propeptide, blocks active site |
The occluding loop (residues 105-116) is unique to cathepsin B among cathepsins, providing:
| Compartment | Function |
|---|---|
| Lysosome | Primary site, optimal pH 5.0 |
| Endosome | Intermediate processing |
| Cytoplasm | Under stress conditions |
| Extracellular | Secreted form (minor) |
| Nucleus | Possible additional functions |
Cathepsin B degrades numerous substrates:
| Substrate Category | Examples | Significance |
|---|---|---|
| Cytosolic proteins | Denatured proteins, aggregates | Quality control |
| Extracellular matrix | Collagen, fibronectin | Remodeling |
| Membrane proteins | receptors, adhesion molecules | Turnover |
| Signaling molecules | Pro-caspases, cyclins | Apoptosis regulation |
Cathepsin B plays critical roles in autophagy[3]:
In immune cells, cathepsin B processes antigens:
Under certain conditions, cathepsin B can be secreted:
Cathepsin B has a complex, context-dependent role in AD[1:1]:
| Function | Evidence | Outcome |
|---|---|---|
| Aβ40/42 degradation | In vitro assays | Reduces Aβ levels |
| Aβ oligomer cleavage | Cell models | Decreases toxicity |
| Plaque colocalization | IHC in AD brain | Spatial relationship |
Therapeutic implications:
Paradoxically, cathepsin B may also contribute to Aβ generation[4]:
| Process | Mechanism |
|---|---|
| APP cleavage | May generate C-terminal fragments |
| BACE activation | May enhance β-secretase activity |
| γ-secretase modulation | Affects Aβ42/Aβ40 ratio |
Cathepsin B directly cleaves tau protein[5]:
| Tau Species | Cleavage Site | Effect |
|---|---|---|
| Full-length tau | Multiple sites | Fragmentation |
| Phospho-tau | Enhanced cleavage | Generates toxic fragments |
| NFT components | Solubilization | May spread pathology |
Cathepsin B contributes to neuronal death[6]:
Cathepsin B is implicated in PD through alpha-synuclein processing[7]:
| Finding | Significance |
|---|---|
| Cleaves α-syn | Generates fragments |
| Inhibits aggregation | May reduce toxicity |
| Altered in PD brain | Disease relevance |
In GBA mutation carriers[8]:
| Evidence | Finding |
|---|---|
| Expression | Elevated in spinal cord of ALS patients |
| Models | Cathepsin B inhibition is protective |
| Mechanisms | May process TDP-43 fragments |
Cathepsin B processes mutant huntingtin[9]:
| Process | Effect |
|---|---|
| Mutant HTT cleavage | Generates toxic fragments |
| Autophagy modulation | Impairs clearance |
| Neuronal death | Contributes to pathology |
Overexpression in various cancers:
| Region | Expression Level | Cell Types |
|---|---|---|
| Cortex | Moderate | Neurons, glia |
| Hippocampus | High | CA1, CA3 neurons |
| Substantia nigra | Moderate | Dopaminergic neurons |
| Cerebellum | Low | Purkinje cells |
| White matter | Variable | Oligodendrocytes |
| Cell Type | Level | Function |
|---|---|---|
| Microglia | High | Phagocytosis, inflammation |
| Astrocytes | Moderate | Metabolic support |
| Neurons | Low-Moderate | Proteostasis |
| Oligodendrocytes | Low | Myelin turnover |
| Endothelial | Moderate | BBB function |
| Approach | Rationale | Challenges |
|---|---|---|
| Activators | Enhance Aβ clearance | May increase neuronal death |
| Inhibitors | Reduce neuronal apoptosis | May impair Aβ clearance |
| Gene therapy | Increase expression | Delivery, regulation |
| Modulators | Fine-tune activity | Specificity |
Small molecule inhibitors have been developed[10]:
| Compound | Selectivity | Stage |
|---|---|---|
| CA-074 | Cathepsin B specific | Research |
| E-64 | Broad cathepsins | Research |
| L-006235 | Brain penetrant | Lead optimization |
| Method | Application |
|---|---|
| Immunohistochemistry | Tissue localization |
| Activity assays | Fluorogenic substrates |
| Western blot | Protein levels |
| qPCR | mRNA expression |
| RNA-seq | Transcriptome |
| System | Use |
|---|---|
| Knockout mice | Functional studies |
| Transgenic mice | Disease models |
| iPSC neurons | Human disease modeling |
| Primary cultures | Mechanism studies |
| Marker | Source | Status |
|---|---|---|
| Cathepsin B activity | CSF | Research |
| CTSB mRNA | Blood | Exploratory |
| Cathepsin B protein | CSF | Research |
| Cathepsin | Function in Neurodegeneration |
|---|---|
| CTSB | Aβ degradation, apoptosis |
| CTSD | Aβ degradation, prominent in AD |
| CTSL | Autophagy, synaptic function |
| CTSH | Less characterized |
| Model | Phenotype | Relevance |
|---|---|---|
| Complete knockout | Viable, fertile, subtle lysosomal changes | Baseline function |
| Neuron-specific KO | Protected from Aβ toxicity | Therapeutic mechanism |
| Microglia-specific KO | Altered inflammatory response | Role in glia |
| Model | Cross | Findings |
|---|---|---|
| APP/PS1 | CTSB-/- | Paradoxical increase in plaques |
| 3xTg-AD | CTSB overexpression | Reduced amyloid, improved cognition |
| MPTP | CTSB inhibition | Protected dopaminergic neurons |
| Mutant HTT | CTSB-/- | Reduced htt fragment toxicity |
| Application | Status | Utility |
|---|---|---|
| CSF cathepsin B | Research | Disease progression marker |
| Blood cathepsin B | Exploratory | Non-invasive screening |
| Brain imaging | Development | Lysosomal dysfunction |
The dual nature of cathepsin B complicates therapeutic targeting:
Solution: Cell-type specific targeting
| Cell Type | Desired Effect | Strategy |
|---|---|---|
| Neurons | Inhibit pro-apoptotic activity | Selective inhibitors |
| Microglia | Enhance phagocytosis | Activators |
| Astrocytes | Modulate metabolism | Balanced approach |
| Pathway | Interaction | Effect |
|---|---|---|
| Autophagy | Substrate, regulator | Bidirectional |
| Apoptosis | Executor, substrate | Activation |
| Inflammation | SASP component | Pro-inflammatory |
| mTOR | Inhibited by cathepsin B | Complex |
| p53 | Regulated by cathepsin B | Feedback loop |
CTSB (Cathepsin B) expression patterns in the human brain:
CTSB is expressed in:
| Region | Expression Level | Data Source |
|---|---|---|
| Substantia Nigra | High | Human MTG |
| Cerebral Cortex | High | Allen Human Brain Atlas |
| Hippocampus | High | Allen Human Brain Atlas |
| Striatum | High | Human MTG |
| Cerebellum | Moderate-High | Allen Human Brain Atlas |
CTSB expression in microglia is particularly relevant for understanding its role in neurodegeneration, as microglial cathepsin B contributes to inflammatory cytokine processing and protein aggregate degradation.
Mueller-Steiner S, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B. Neuron. 2006. ↩︎ ↩︎
Hook VY, et al. Cathepsin B is a new drug target for neurodegenerative diseases. Drug News Perspect. 2008. ↩︎
Wolfe DM, et al. Autophagy failure in Alzheimer's disease. Exp Neurol. 2010. ↩︎
Han M, et al. Cathepsin B in amyloid-beta production. J Neurochem. 2019. ↩︎
Zhou Y, et al. Cathepsin B mediates tau cleavage. Cell Death Dis. 2019. ↩︎
Cunningham CC, et al. Activation of the lysosomal cysteine protease cathepsin B in neuronal apoptosis. J Biol Chem. 2005. ↩︎
Kim J, et al. Cathepsin B degrades alpha-synuclein in Parkinson's disease. Nat Neurosci. 2008. ↩︎
Melman A, et al. Lysosomal dysfunction in GBA-associated Parkinson's disease. J Neurosci. 2019. ↩︎
Yang Y, et al. Cathepsin B in Huntington's disease. Nat Commun. 2021. ↩︎
Bahety P, et al. Cathepsin B small molecule inhibitors for AD. ACS Med Chem Lett. 2019. ↩︎